Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHONQUER: ivosidenib versus placebo in IDH1-mutant advanced conventional chondrosarcoma
2023-508507-20-00Phase 3Authorised
- Sponsor
- Servier
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in chondrosarcoma comparing Ivosidenib with Placebo (2 arms). Primary endpoint: Progression-free survival. Planned start Apr 2025; status: authorised.
02
Drugs
ivosidenib
03
Conditions
chondrosarcoma
Beyond the preview
Go deeper on 2023-508507-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508507-20-00.